Introduction
============

A growing number of preclinical studies showed that overexpression of cyclooxygenase-2 (COX-2) had been implicated as a tumor-initiating and tumor-promoting event for several common solid tumors, including lung, breast, and colon cancers.[@b1-ott-11-721]--[@b3-ott-11-721] Approximately 70% of adenocarcinomas in non-small-cell lung cancer (NSCLC) have been found to exhibit increased COX-2 expression.[@b4-ott-11-721] COX-2 expression in tumors appears to be instrumental in tumor resistance to apoptosis, angiogenesis, invasion, and immune suppression.[@b5-ott-11-721] Further, selective COX-2 inhibitors have been shown to inhibit the growth of lung cancer cell lines and to enhance the effectiveness of selected chemotherapy against NSCLC cell lines in xenograft models.[@b6-ott-11-721] These studies[@b5-ott-11-721],[@b7-ott-11-721] suggest nonsteroidal anti-inflammatory drugs (NSAIDs) may act on multiple tumor-progression targets via both COX-2-dependent and -independent pathways. Based on these observations, COX-2 inhibitors have been evaluated in combination with chemotherapy for the management of metastatic NSCLC in patients who have failed prior chemotherapy. However, current clinical trials on the benefit of COX-2 inhibitors in cancer treatment report conflicting results. Indeed, some studies[@b2-ott-11-721],[@b4-ott-11-721],[@b6-ott-11-721] demonstrated that COX-2 inhibitors could enhance antitumor activity of conventional anticancer agents in vitro and in vivo. However, many studies have confirmed that COX-2 inhibitors did not appear to enhance efficacy or improve patient-reported symptoms and can also lead to certain toxicity.[@b8-ott-11-721],[@b9-ott-11-721]

There are three meta-analyses[@b10-ott-11-721]--[@b12-ott-11-721] about the efficacy and safety profile of COX-2 inhibitors that have been published. All the three studies reported that COX-2 inhibitors could increase overall response rate (ORR) in patients with advanced NSCLC. Of these, two studies[@b10-ott-11-721],[@b11-ott-11-721] indicated that celecoxib significantly increased risk of hematologic toxicities, while Chen et al[@b12-ott-11-721] reported that COX-2 inhibitors plus chemotherapy was associated with a higher incidence of cardiovascular events compared with chemotherapy alone. Two meta-analyses[@b10-ott-11-721],[@b12-ott-11-721] did not carry out a hazard ratio (HR) analysis of outcome indicators overall survival (OS) and progression-free survival (PFS). While conducting meta-analysis, Hou et al[@b10-ott-11-721] and Chen et al[@b12-ott-11-721] only focused on celecoxib. Moreover, Hou et al[@b10-ott-11-721] included six studies with 1,181 patients, describing all end points without subgroup analysis. To better assess the efficacy and safety profile of COX-2 inhibitors combined with chemotherapy for patients with advanced NSCLC, the meta-analysis of data from published randomized controlled trials (RCTs) in this field was performed.

Materials and methods
=====================

Literature search strategy
--------------------------

This meta-analysis was reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.[@b13-ott-11-721] Systematic computerized searches of PubMed, Embase, and Cochrane data bases for reports dated up to March 26, 2017 were performed with the following search terms: "cyclooxygenase-2 inhibitor", "COX-2 inhibitor", "non-small-cell lung cancer", "NSCLC", "chemotherapy". All reference lists from the trials selected by electronic searching were scanned to further identify relevant trials. Ethical approval was not required for this study.

Literature selection and exclusion
----------------------------------

The following criteria were used for study selection: 1) the RCTs compared the efficacy and safety profile of adding COX-2 inhibitors to chemotherapy alone; 2) only including patients with cytologically or histologically confirmed NSCLC stage IIIB or IV; 3) full paper in English language was published; and 4) studies needed to have measured at least one of the following outcomes as their end points: OS, PFS, 1-year survival rate (SR), ORR, and toxicities.

If a study was a duplicate or the study's data could not be extracted or obtained through contact with the author, it was excluded from our analysis.

Data extraction
---------------

The final articles included were independently assessed by two authors. In the case of disagreement, another author was consulted to resolve the dispute, and a final decision was made by majority vote. The relevant information included study design, patient characteristics, interventions, controls, and outcomes. For some missing survival indices such as OS and PFS, HR and 95% confidence interval (CI) were extracted from the survival curve.[@b14-ott-11-721] Regarding toxicity, we considered both hematological (leukopenia, thrombocytopenia, and anemia) and nonhematological (nausea/vomiting, diarrhea, asthenia, and cardiotoxicity) grade 3 and grade 4 effects of treatment.

Quality assessment of included studies
--------------------------------------

Two investigators independently evaluated the methodological quality of eligible trials using the Cochrane collaboration tool for assessing risk of bias[@b15-ott-11-721] (random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias).

Statistical analysis
--------------------

Dichotomous data, including 1-year SR, ORR, and toxicities, were compared with a pooled risk ratio (RR) with a 95% CI. Survival indices of OS and PFS were expressed as HR with a 95% CI.[@b16-ott-11-721],[@b17-ott-11-721] This meta-analysis was performed using Stata 12.0. Heterogeneity between studies was also analyzed using chi-square tests, with the significance level set to *P*\<0.1.[@b18-ott-11-721] No heterogeneity was observed when *I*^2^=0%. However, when *I*^2^\>50%, studies were considered to have significant heterogeneity. If the data were homogeneous under a fixed-effects model, the type of COX-2 inhibitors and treatment line were identified as key sources of heterogeneity in the main outcomes (OS, PFS, 1-year SR, and ORR).[@b18-ott-11-721] Heterogeneity was then dealt with using subgroups based on these modifiers. If the data were still heterogeneous, we introduced a random-effects model. Whereas when *I*^2^\<50%, a fixed-effects model was used instead.[@b18-ott-11-721]

A funnel plot was used to estimate potential publication bias, with an asymmetric plot suggesting possible bias.[@b19-ott-11-721] In the funnel plot, larger studies that provide a more precise estimate of an interventions effect form the spout of the funnel, whereas smaller studies with less precision form the cone end of the funnel. Finally, the Egger's test was employed to address quantitative detection bias.[@b20-ott-11-721]

Results
=======

Characteristics of individual studies
-------------------------------------

We identified 407 publications from the electronic databases ([Figure 1](#f1-ott-11-721){ref-type="fig"}), of which 86 were excluded as duplicates and 273 were excluded based on selection criteria. This resulted in 48 articles, which were independently read by two authors. Eventually, six studies[@b21-ott-11-721]--[@b26-ott-11-721] involving 1,794 patients were included in our meta-analysis. The characteristics of each individual study are presented in [Table 1](#t1-ott-11-721){ref-type="table"}.

Quality of the included studies
-------------------------------

The risk of bias in the included studies was strictly evaluated. Four studies[@b23-ott-11-721]--[@b26-ott-11-721] describe a random component in the sequence generation process and the concealment of treatment allocation, and the four trials[@b23-ott-11-721]--[@b26-ott-11-721] were designed as double-blind trials. In addition, one study[@b22-ott-11-721] lost large amounts of data, which may lend to a certain attrition bias. Details of methodological approch are presented in [Table 2](#t2-ott-11-721){ref-type="table"}.

Overall survival
----------------

All studies[@b21-ott-11-721]--[@b26-ott-11-721] including 1,794 patients reported HR for OS. When assessing the effect on OS (as shown in [Figure 2](#f2-ott-11-721){ref-type="fig"}), COX-2 inhibitors plus chemotherapy did not significantly differ from chemotherapy alone (HR =1.04, 95% CI: 0.91--1.18, *I*^2^=0.0%, *P*=0.808). Further, we conducted two subgroup analyses according to the type of COX-2 inhibitors (celecoxib, rofecoxib, or apricoxib) and treatment line (first or second). Unfortunately, no clinical benefit in OS was found among the groups: celecoxib (HR =1.05, 95% CI: 0.90--1.22, *I*^2^=0.0%, *P*=0.532), rofecoxib (HR =1.00, 95% CI: 0.75--1.34, *I*^2^= not applicable \[NA\], *P*=NA), apricoxib (HR =1.04, 95% CI: 0.64--1.69, *I*^2^=NA, *P*=NA), first-line treatment (HR =1.01, 95% CI: 0.88--1.16, *I*^2^=0.0%, *P*=0.819), and second-line treatment (HR =1.19, 95% CI: 0.88--1.60, *I*^2^=0.0%, *P*=0.508).

Progression-free survival
-------------------------

All studies[@b21-ott-11-721]--[@b26-ott-11-721] including 1,794 patients reported HR for PFS. We also assessed the effect on PFS (summarized in [Figure 3](#f3-ott-11-721){ref-type="fig"}), and found that COX-2 inhibitors plus chemotherapy did not significantly differ from chemotherapy alone (HR =0.97, 95% CI: 0.86--1.10, *I*^2^=0.0%, *P*=0.849). As previously mentioned, we also performed two subgroup analyses. However, no significant differences were obtained in the following groups: celecoxib (HR =0.96, 95% CI: 0.83--1.12, *I*^2^=0.0%, *P*=0.584), rofecoxib (HR =1.00, 95% CI: 0.76--1.31, *I*^2^=NA, *P*=NA), apricoxib (HR =0.97, 95% CI: 0.58--1.62, *I*^2^=NA, *P*=NA), first-line treatment (HR =0.97, 95% CI: 0.84--1.11, *I*^2^=0.0%, *P*=0.578), or second-line treatment (HR =0.99, 95% CI: 0.74--1.33, *I*^2^=0.0%, *P*=0.924).

One-year survival rate
----------------------

Five RCTs including 1,482 patients reported 1-year mortality rate figures. We next evaluated the effect on 1-year SR (summarized in [Figure 4](#f4-ott-11-721){ref-type="fig"}). COX-2 inhibitors plus chemotherapy did not significantly differ from chemotherapy alone (RR =1.03, 95% CI: 0.89--1.20, *I*^2^=0.0%, *P*=0.531). Moreover, when grouped by the type of COX-2 inhibitors, subgroup analysis also did not yield significant results: celecoxib (RR =1.03, 95% CI: 0.86--1.22, *I*^2^=36.3%, *P*=0.208), rofecoxib (RR =1.06, 95% CI: 0.78--1.44, *I*^2^=NA, *P*=NA), or apricoxib (RR =1.00, 95% CI: 0.15--6.72, *I*^2^=NA, *P*=NA). Similar results were found in the subgroup analysis according to treatment line: first-line treatment (RR =1.08, 95% CI: 0.92--1.27, *I*^2^=0.0%, *P*=0.958) and second-line treatment (RR =0.68, 95% CI: 0.41--1.14, *I*^2^=0.0%, *P*=0.676).

Overall response rate
---------------------

Four RCTs including 1,410 patients reported ORR. When evaluating the effect on ORR (summarized in [Figure 5](#f5-ott-11-721){ref-type="fig"}), COX-2 inhibitors combined with chemotherapy were found to be more effective than chemotherapy alone (RR =1.25, 95% CI: 1.06--1.48, *I*^2^=0.0%, *P*=0.420). To better assess the efficacy of COX-2 inhibitors for advanced NSCLC, we also conducted further subgroup analysis. Significantly increased ORRs were observed for rofecoxib (RR =1.56, 95% CI: 1.08--2.25, *I*^2^=NA, *P*=NA) and first-line treatment (RR =1.27, 95% CI: 1.07--1.50, *I*^2^=0.0%, *P*=0.451). Whereas celecoxib (RR =1.18, 95% CI: 0.98--1.42, *I*^2^=0.0%, *P*=0.562) and second-line treatment with COX-2 inhibitors for patients with advanced NSCLC showed no significant difference (RR =0.49, 95% CI: 0.09--2.60, *I*^2^=NA, *P*=NA).

Toxicities
----------

Finally, we assessed the toxicities of COX-2 inhibitors plus chemotherapy for patients with advanced NSCLC. Results indicated that grade 3 and grade 4 toxicities of leukopenia, thrombocytopenia, and cardiovascular events increased with the addition of COX-2 inhibitors: leukopenia (RR =1.21, 95% CI: 1.03--1.42, *I*^2^=0.0%, *P*=0.499), thrombocytopenia (RR =1.32, 95% CI: 1.04--1.67, *I*^2^=0.0%, *P*=0.560), and cardiotoxicity (RR =2.39, 95% CI: 1.06--5.42, *I*^2^=0.0%, *P*=0.690). However, significantly increased risks of other toxicities (anemia, nausea/vomiting, diarrhea, asthenia) and grade 3 and grade 4 effects of treatment were not found. Detailed data are listed in [Table 3](#t3-ott-11-721){ref-type="table"}.

Publication bias
----------------

No publication bias was observed for any of the outcomes based on the symmetry of the funnel plots. Furthermore, the results of the Egger's test indicated no significant difference in primary outcomes: OS (bias =0.708, 95% CI: −3.086 to 4.051, *P*=0.632), PFS (bias =−0.387, 95% CI: −4.508 to 3.733, *P*=0.807), ORR (bias =−0.835, 95% CI: −6.033 to 4.363, *P*=0.561), and 1−year SR (bias =−0.940, 95% CI: −3.748--1.869, *P*=0.365).

Discussion
==========

In this meta-analysis, we evaluated six clinical trials that included 1,794 advanced NSCLC patients. Our meta-analysis indicated a significantly increased ORR with COX-2 inhibitors plus chemotherapy over chemotherapy alone. COX-2 is reported to interfere with angiogenesis, apoptosis, and tumor invasiveness.[@b27-ott-11-721] Increased expression of COX-2 has been found in lung cancer and has been associated with worse prognosis.[@b28-ott-11-721],[@b29-ott-11-721] COX-2 inhibitors inhibit the growth of human lung cancer cells as single agents as well as in combination with chemotherapy. Subgroup analysis reported that rofecoxib rather than celecoxib may produce a significantly increased ORR of advanced NSCLC with chemotherapy. Zhou et al[@b11-ott-11-721] found that both celecoxib and rofecoxib can improve the ORR of advanced NSCLC with chemotherapy. Inconsistencies in these results may be due to a different sample size. The celecoxib plus chemotherapy subgroup of Zhou et al contained six RCTs, whereas this study included four RCTs. In addition, Zhou et al and this meta-analysis included only one trial on rofecoxib, and so the reliability of the results may be reduced and further research with a large sample is needed to confirm these results. According to treatment line, we observed a statistically significant favorable effect of first-line chemotherapy with COX-2 inhibitors on ORR but no change in second-line chemotherapy. Since there was only one study (by Lilenbaum et al[@b21-ott-11-721]) which included COX-2 inhibitors as second-line chemotherapy, more research is needed to verify this conclusion. However, there was no significant difference found in 1-year SR of advanced NSCLC between COX-2 inhibitors plus chemotherapy and chemotherapy alone. In the subgroup analysis that was based on the type of COX-2 inhibitors and treatment line, 1-year SR also did not change between COX-2 inhibitors plus chemotherapy and chemotherapy alone. Similar results were obtained for OS and PFS. In all subgroup analyses, COX-2 inhibitors plus chemotherapy showed no significant influence on OS and PFS compared with chemotherapy alone. Three studies[@b10-ott-11-721]--[@b12-ott-11-721] reported results consistent with this study, where COX-2 inhibitors plus chemotherapy had no advantage over 1-year SR compared to chemotherapy alone. Only Zhou et al[@b11-ott-11-721] calculated pooled HR of OS and PFS, and indicated that difference in OS and PFS durations of patients on COX-2 inhibitors plus chemotherapy and chemotherapy alone was not statistically significant. There has been no research to report that COX-2 inhibitors plus chemotherapy can reduce mortality of patients with advanced NSCLC. Therefore, further study on how to improve the 1-year SR, OS, or PFS of patients with advanced NSCLC is still necessary. The abovementioned results showed that COX-2 inhibitors may increase ORR of chemotherapy with advanced NSCLC, especially combined with first-line treatment. However, no similar change was found in the survival indices.

Toxicities were graded according to Common Terminology Criteria for Adverse Events v3.0 of the National Cancer Institute.[@b30-ott-11-721] This meta-analysis included both hematological and nonhematological grade 3 and grade 4 side effects of treatment. A higher frequency of leukopenia, thrombocytopenia, and cardiotoxicity was observed in COX-2 inhibitors plus chemotherapy compared to chemotherapy alone. Few studies[@b31-ott-11-721]--[@b33-ott-11-721] reported that coordination of COX-2 with vascular endothelial growth factor (VEGF) may promote angiogenesis in bone marrow after chemotherapy. Pharmacodynamic studies suggested that COX-2 inhibitors can inhibit angiogenesis by inhibiting the VEGF, basic fibroblast growth factor, platelet-derived growth factor, and endothelin 21,[@b31-ott-11-721] which was a possible explanation for a higher frequency of leukopenia and thrombocytopenia in COX-2 inhibitors plus chemotherapy. The induction of cardiovascular events by COX-2 inhibitors limits its applications and research for cancer. Chen et al[@b12-ott-11-721] reported that the risk of cardiovascular events was significantly increased in patients with long-term use of celecoxib, whereas the other meta-analyses did not find that COX-2 inhibitors used for treating NSCLC could increase the risk of cardiovascular events.[@b10-ott-11-721],[@b11-ott-11-721] In an attempt to answer the questions about the cardiovascular safety of NSAIDs and COX-2 inhibitors, many physician-scientists have undertaken research efforts. Innumerable observational studies examining larger and larger administrative databases have been sought to answer these critical questions. However, cardiovascular toxicity of COX-2 inhibitors still remains a debated topic in the field.

There are several limitations to this study that should be addressed. First, only a few clinical trials met the inclusion and exclusion criteria. Consequently, more clinical studies will be required to confirm our results. Second, not all RCTs provided sufficient data on response rates and survival indices, which affected the pooled results in the present meta-analysis. Finally, one study had lost large amounts of data, and there may be a certain attrition bias.

Conclusion
==========

This meta-analysis indicated that COX-2 inhibitors, especially rofecoxib, improved ORR of advanced NSCLC with chemotherapy, but had no effect on survival indices. Accordingly, COX-2 inhibitors may lead to higher rates of hematologic toxicities and cardiovascular events. Based on these findings, benefits versus hazards of COX-2 inhibitors for treating advanced NSCLC need to be carefully considered.
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###### 

The characteristics of each individual study

  Study                              Year   Phase   Study period                      Country           Sample (I/C)    Age (years) (I/C)             Male (female) (I/C)   Histology, I/C           
  ---------------------------------- ------ ------- --------------------------------- ----------------- --------------- ----------------------------- --------------------- ---------------- ------- -------
  Lilenbaum et al[@b21-ott-11-721]   2006   II      February 2002 to September 2003   USA               133 (67/66)     62.7 (37--84)/63.5 (41--78)   40 (27)/40 (26)       NA               NA      NA
  Gridelli et al[@b22-ott-11-721]    2007   III     January 2003 to May 2005          Italy             400 (149/251)   61.5 (29--71)/59 (37--70)     120 (29)/202 (49)     68/134           47/53   34/64
  Koch et al[@b23-ott-11-721]        2011   III     May 2003 to May 2006              Sweden            316 (158/158)   66 (38--85)/65 (37--85)       73 (85)/87 (71)       77/94            38/27   43/36
  Groen et al[@b24-ott-11-721]       2011   III     July 2003 to December 2007        the Netherlands   561 (281/280)   62 (40--84)/61 (33--84)       184 (97)/171 (109)    138/132          44/57   99/91
  Edelman et al[@b25-ott-11-721]     2015   II      NA                                USA               72 (36/36)      62/66                         20 (16)/20 (16)       24/25            8/6     4/5
  Edelman et al[@b26-ott-11-721]     2017   III     November 2013 to January 2016     USA               312 (154/158)   64 (38--83)/64 (36--89)       82 (72)/87 (71)       NA               44/43   NA

**Note:** Data are presented as mean (range) unless otherwise specified.

**Abbreviations:** I/C, interventions/control; NA, not applicable.

###### 

The risk of bias in the included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                              Year   Country           Random sequence generation                    Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Other bias                Extent of disease, stage   ECOG\   Treatment line   Interventions                                                                                                                                                              Control                                                                                                                                     Follow-up (months)
                                                                                                                                                                                                                                                                                                                    PS                                                                                                                                                                                                                                                                                                                                              
  ---------------------------------- ------ ----------------- --------------------------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- ------------------------- -------------------------- ------- ---------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  Lilenbaum et al[@b21-ott-11-721]   2006   USA               Not reported                                  Not reported             Not reported                             Not reported                     Intent to treat           Not reported          No other source of bias   IIIB, IV                   ECOG\   Second           Celecoxib 400 mg po bid + DTX 35 mg m^−2^ or GEM 1,000 mg m^−2^ + CPT-11 60--100 mg m^−2^ ivgtt day 1 and 8 day, q3w                                                       DTX 35 mg m^−2^ or GEM 1,000 mg m^−2^ + CPT-11 60--100 mg m^−2^ ivgtt day 1 and 8 day, q3w                                                  19
                                                                                                                                                                                                                                                                                                                    0--1                                                                                                                                                                                                                                                                                                                                            

  Gridelli et al[@b22-ott-11-721]    2007   Italy             Not reported                                  Not reported             Not reported                             Not reported                     Intent to treat           Not reported          No other source of bias   IIIB, IV                   ECOG\   First            Rofecoxib 50 mg po qd + GEM 1,200 mg m^−2^ in 30-minute or PCI GEM 1,200 mg m^−2^ over 120-minute iv infusions days 1 and 8 + DDP 80 mg m^−2^ ivgtt qd day 1, q3w          GEM 1,200 mg m^−2^ in 30-minute or PCI GEM 1,200 mg m^−2^ over 120-minute iv infusions days 1 and 8 + DDP 80 mg m^−2^ ivgtt qd day 1, q3w   28
                                                                                                                                                                                                                                                                                                                    0--1                                                                                                                                                                                                                                                                                                                                            

  Koch et al[@b23-ott-11-721]        2011   Sweden            Minimization                                  Central allocation       Yes                                      Not reported                     Intent to treat           Not reported          No other source of bias   IIIB, IV                   ECOG\   First            Celecoxib 400 mg po bid + GEM or NVB + CBP or DDP, ivgtt q3w[\*](#tfn3-ott-11-721){ref-type="table-fn"}                                                                    Placebo + GEM or NVB + CBP or DDP, ivgtt q3w                                                                                                36
                                                                                                                                                                                                                                                                                                                    0--2                                                                                                                                                                                                                                                                                                                                            

  Groen et al[@b24-ott-11-721]       2011   the Netherlands   Centralized                                   Not reported             Not reported                             Yes                              Intent to treat           Not reported          No other source of bias   IIIB, IV                   ECOG\   First            Celecoxib 400 mg po bid + DTX 75 mg m^−2^ ivgtt qd day 1 + CBP ivgtt qd day 1, q3w[\*\*](#tfn4-ott-11-721){ref-type="table-fn"}                                            Placebo + DTX 75 mg m^−2^ ivgtt qd day 1 + CBP ivgtt qd day 1, q3w                                                                          53
                                                                                                                                                                                                                                                                                                                    0--2                                                                                                                                                                                                                                                                                                                                            

  Edelman et al[@b25-ott-11-721]     2015   USA               Centralized                                   Central allocation       Yes                                      Not reported                     Intent to treat           Not reported          No other source of bias   IIIB, IV                   ECOG\   Second           Apricoxib 400 mg po qd + DTX 75 mg m^−2^ or PET 500 mg m^−2^, q3w                                                                                                          Placebo 400 mg po qd DTX 75 mg m^−2^ or PET 500 mg m^−2^, q3w                                                                               NA
                                                                                                                                                                                                                                                                                                                    0--2                                                                                                                                                                                                                                                                                                                                            

  Edelman et al[@b26-ott-11-721]     2017   USA               Stratified random-permuted-blocks procedure   Central allocation       Yes                                      Not reported                     Intent to treat           Not reported          No other source of bias   IIIB, IV                   ECOG\   First            Celecoxib 400 mg po bid + CBP + PET 500 mg m^−2^ day 1, q3w for nonsquamous or celecoxib 400 mg po bid + CBP day 1+ GEM 1,000 mg m^−2^ day 1 and day 8, q3w for squamous   Placebo + CBP + PET 500 mg m^−2^ day 1, q3w for nonsquamous or placebo + CBP day 1 + GEM 1,000 mg m^−2^ day 1 and day 8, q3w for squamous   31
                                                                                                                                                                                                                                                                                                                    0--2                                                                                                                                                                                                                                                                                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

The dose of chemotherapeutic agents was not mentioned in the trial;

the dose of carboplatin was not mentioned in the trial.

**Abbreviations:** bid, twice daily; CBP, carboplatin; d, day; DDP, cisplatin; DTX, docetaxel; iv, intravenously; ECOG PS, Eastern Cooperative Oncology Group performance status; GEM, gemcitabine; ivgtt, intravenous drip; PCI, prolonged constant infusion; NVB, vinorelbine; PET, pemetrexed; po, orally; q, every; w, weeks.

###### 

Meta-analysis of the toxicities in patients with advanced NSCLC

  Toxicity           Number of RCTs   RR (95% CI)         *P*-value for RR   *I*^2^ for heterogeneity   *P*-value for heterogeneity
  ------------------ ---------------- ------------------- ------------------ -------------------------- -----------------------------
  Leukopenia         6                1.21 (1.03--1.42)   0.017              0.0%                       0.499
  Thrombocytopenia   6                1.32 (1.04--1.67)   0.020              0.0%                       0.56
  Anemia             4                1.27 (0.71--2.27)   0.416              12.0%                      0.333
  Nausea             4                0.70 (0.39--1.25)   0.228              0.0%                       0.969
  Diarrhea           3                1.31 (0.64--2.71)   0.460              41.6%                      0.180
  Asthenia           5                0.78 (0.50--1.23)   0.289              0.0%                       0.531
  Cardiotoxicity     5                2.39 (1.06--5.42)   0.037              0.0%                       0.690

**Abbreviations:** RCTs, randomized controlled trials; NSCLC, non-small-cell lung cancer; RR, risk ratio.
